0000899243-21-027295.txt : 20210702 0000899243-21-027295.hdr.sgml : 20210702 20210702175006 ACCESSION NUMBER: 0000899243-21-027295 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210615 FILED AS OF DATE: 20210702 DATE AS OF CHANGE: 20210702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JORDAN WADIH CENTRAL INDEX KEY: 0001222090 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 211071751 MAIL ADDRESS: STREET 1: ANTIGENICS INC. STREET 2: 162 FIFTH AVE., SUITE 900 CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-15 0 0001098972 AGENUS INC AGEN 0001222090 JORDAN WADIH C/O AGENUS INC. 3 FORBES ROAD LEXINGTON MA 02421 1 0 0 0 Stock Option 3.18 2021-06-15 4 A 0 100000 0.00 A 2030-12-17 Common Stock 100000 100000 D Deferred Stock Units 2021-07-01 4 A 0 6870.871 A Common Stock 6870.871 195006.2 D Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022. Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. $3.820 per Deferred Stock Unit acquired on July 1, 2021. The price of each Deferred Stock Unit acquired prior to July 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. /s/ Adam Krauss, as Attorney-in-Fact for Wadih Jordan 2021-07-02